Lead Product(s) : AP-002
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Aerogen
Deal Size : $212.5 million
Deal Type : Licensing Agreement
Details : The licensing agreement grants Nuance the exclusive rights to develop and commercialize AeroFact™, an innovate new therapy combining a well‐established pulmonary surfactant drug with proprietary vibrating mesh nebulizer aerosolization technology, in ...
Brand Name : AeroFact
Molecule Type : Small molecule
Upfront Cash : $20.0 million
December 22, 2021
Lead Product(s) : AP-002
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Aerogen
Deal Size : $212.5 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?